Compare Saakshi Medtech with Similar Stocks
Total Returns (Price + Dividend) 
Saakshi Medtech for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News
How has been the historical performance of Saakshi Medtech?
Answer: The historical performance of Saakshi Medtech shows significant fluctuations in key financial metrics over the years. Breakdown: Saakshi Medtech's net sales have decreased from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25, reflecting a downward trend. The total operating income followed a similar pattern, dropping from 122.06 Cr in Mar'23 to 92.43 Cr in Mar'25. The raw material costs also decreased from 73.93 Cr in Mar'23 to 58.81 Cr in Mar'25, indicating a reduction in production costs. Operating profit (PBDIT) saw a decline from 20.70 Cr in Mar'23 to 10.88 Cr in Mar'25, with the operating profit margin decreasing from 16.84% to 11.15%. Profit before tax fell from 16.59 Cr in Mar'23 to 6.59 Cr in Mar'25, leading to a profit after tax of 4.71 Cr in Mar'25, down from 12.38 Cr in Mar'23. The company's total assets increased from 93.24 Cr in Mar'23 to 131.10 Cr in Mar'25, while total liabilities also ros...
Read full news articleIs Saakshi Medtech overvalued or undervalued?
As of 6 November 2025, the valuation grade for Saakshi Medtech has moved from expensive to very expensive. The company is currently overvalued, indicated by a PE ratio of 65.09, an EV to EBITDA ratio of 31.15, and a Price to Book Value of 3.13. In comparison to its peers, Adani Enterprises has a PE ratio of 127.79 and an EV to EBITDA of 29.94, while Tata Chemicals shows a PE of 60.22 and an EV to EBITDA of 16.15, suggesting that Saakshi Medtech's valuation is significantly higher than many of its competitors. The company's recent performance has also been underwhelming, with a year-to-date return of -22.64%, contrasting sharply with the Sensex's gain of 7.89% over the same period. This further reinforces the notion that Saakshi Medtech is not only overvalued but also struggling to deliver returns in the current market environment....
Read full news article Announcements 
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 2 FIIs (0.1%)
Chitra Vijay Latkar (66.27%)
Jatinder Agarwal (4.84%)
22.37%
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 21.56% vs 7.89% in Mar 2025
Growth in half year ended Sep 2025 is 426.19% vs -63.48% in Mar 2025
Annual Results Snapshot (Standalone) - Mar'25
YoY Growth in year ended Mar 2025 is -24.14% vs -0.17% in Mar 2024
YoY Growth in year ended Mar 2025 is -59.15% vs -6.87% in Mar 2024






